lung cancer

Views & Analysis

The Frauenkirche is a church in the Bavarian city of Munich that serves as the cathedral of the Archdiocese of Munich and Freising and seat of its Archbishop.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.

News

Roche's Tecentriq posts trial wins in two key indications

Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with

News

BMS Opdivo fails in small cell lung cancer

Bristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with small cell lung cancer, who had relapsed following platinum-based chemother

News

US regulator backs Pfizer's Vizimpro lung cancer drug

The US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients whose tumours have a certain mutation.

News

Latest lung cancer data could open new avenue for Roche's Te...

Roche is eyeing a new use for its checkpoint inhibitor immunotherapy Tecentriq after it posted results showing it extended patients’ lives by an extra two months compared with chemotherapy

News

AZ grabs EU approval for Imfinzi in advanced lung cancer

The European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was previously only treatable with chemotherapy.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Roche's Tecentriq posts trial wins in two key indications

BMS Opdivo fails in small cell lung cancer

US regulator backs Pfizer's Vizimpro lung cancer drug

Latest lung cancer data could open new avenue for Roche's Te...

AZ grabs EU approval for Imfinzi in advanced lung cancer

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

lung cancer

Editor's Picks